Methods| We performed a prospective observational cohort study at the Neurocenter of
Southern Switzerland. Inclusion criteria were a diagnosis of MS (using the 2017 McDonald …

Methods| Patients from 3 university hospitals who were enrolled beginning on March 23,
2021, in an ongoing observational cohort study on immune responses after 2 doses of …

Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS …

Importance B-cell–depleting therapies may affect the development of a protective immune
response following vaccination. Understanding the ability to develop vaccine-specific …

Importance The SARS-CoV-2 variant B. 1.1. 529 (Omicron) escapes neutralizing antibodies
elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is …

Vaccination against SARS-CoV-2 is critical to control the pandemic. Although there are not
yet sufficient data regarding the COVID-19 risk of patients with multiple sclerosis (MS), it is …

Methods| This is a prospective cohort study conducted at the MS Center Amsterdam in
Amsterdam, the Netherlands. On July 31, 2020, all adult patients with a current diagnosis of …

The introduction of a third‐dose vaccination along with new variants of concern raises
questions regarding serology and T‐cell responses in patients with multiple sclerosis …

Background SARS-CoV-2 seroconversion rate after COVID-19 may be influenced by
disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) or neuromyelitis …

Abstract Introduction Responses to SARS‐CoV‐2 vaccination in patients with MS (pwMS)
varies by disease‐modifying therapies (DMTs). We perform a meta‐analysis and systematic …